tetano
Editor, Senior Moderator
Nat Commun
. 2025 Jul 1;16(1):5933.
doi: 10.1038/s41467-025-60938-4. Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase
Amanda K Rudman Spergel[SUP] 1 [/SUP], Ivan T Lee[SUP] 1 [/SUP], Kindra Koslovsky[SUP] 1 [/SUP], Kristi Schaefers[SUP] 1 [/SUP], Andrei Avanesov[SUP] 1 [/SUP], Douglas K Logan[SUP] 2 [/SUP], John Hemmersmeier[SUP] 3 [/SUP], David Ensz[SUP] 4 [/SUP], Daniel Stadlbauer[SUP] 1 [/SUP], Bo Hu[SUP] 1 [/SUP], Alicia Pucci[SUP] 1 [/SUP], Jignesh Vakil[SUP] 1 [/SUP], Robert Paris[SUP] 1 [/SUP], Jintanat Ananworanich[SUP] 1 [/SUP], Raffael Nachbagauer[SUP] 5 [/SUP]
Affiliations
Current influenza vaccines induce immune responses to hemagglutinin (HA), a surface glycoprotein of seasonal influenza viruses, but have suboptimal effectiveness. mRNA vaccines may improve protection by targeting additional antigens such as neuraminidase (NA), for which immune responses independently correlate with protection. In this phase 1/2 trial (NCT05333289), healthy adults 18-75 years were randomly assigned to receive different doses of mRNA-1020 or mRNA-1030 (encoding HA and NA at different ratios), mRNA-1010 (encoding HA), or a licensed active comparator (recombinant HA). Primary endpoints were safety and reactogenicity, and HA and NA antibody responses against vaccine-matched influenza strains. Most common local and systemic solicited ARs were injection site pain and fatigue. There were no vaccine-related serious adverse events nor significant associated safety concerns through 181 days. mRNA-1020 and mRNA-1030 elicited high HA-specific immune responses and induced NA-specific immune responses with no additional reactogenicity at equivalent dose levels beyond an mRNA-based, HA-only-containing vaccine.
. 2025 Jul 1;16(1):5933.
doi: 10.1038/s41467-025-60938-4. Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase
Amanda K Rudman Spergel[SUP] 1 [/SUP], Ivan T Lee[SUP] 1 [/SUP], Kindra Koslovsky[SUP] 1 [/SUP], Kristi Schaefers[SUP] 1 [/SUP], Andrei Avanesov[SUP] 1 [/SUP], Douglas K Logan[SUP] 2 [/SUP], John Hemmersmeier[SUP] 3 [/SUP], David Ensz[SUP] 4 [/SUP], Daniel Stadlbauer[SUP] 1 [/SUP], Bo Hu[SUP] 1 [/SUP], Alicia Pucci[SUP] 1 [/SUP], Jignesh Vakil[SUP] 1 [/SUP], Robert Paris[SUP] 1 [/SUP], Jintanat Ananworanich[SUP] 1 [/SUP], Raffael Nachbagauer[SUP] 5 [/SUP]
Affiliations
- PMID: 40595624
- PMCID: PMC12216828
- DOI: 10.1038/s41467-025-60938-4
Current influenza vaccines induce immune responses to hemagglutinin (HA), a surface glycoprotein of seasonal influenza viruses, but have suboptimal effectiveness. mRNA vaccines may improve protection by targeting additional antigens such as neuraminidase (NA), for which immune responses independently correlate with protection. In this phase 1/2 trial (NCT05333289), healthy adults 18-75 years were randomly assigned to receive different doses of mRNA-1020 or mRNA-1030 (encoding HA and NA at different ratios), mRNA-1010 (encoding HA), or a licensed active comparator (recombinant HA). Primary endpoints were safety and reactogenicity, and HA and NA antibody responses against vaccine-matched influenza strains. Most common local and systemic solicited ARs were injection site pain and fatigue. There were no vaccine-related serious adverse events nor significant associated safety concerns through 181 days. mRNA-1020 and mRNA-1030 elicited high HA-specific immune responses and induced NA-specific immune responses with no additional reactogenicity at equivalent dose levels beyond an mRNA-based, HA-only-containing vaccine.